Since the expression of LAG3, GZMK, FXYD2, and TRBV20-1 was higher than that of PD-1 in the exhausted T-cell subcluster, our data revealed that LGA3, GZMK, FXYD2, and TRBV20-1 may serve as potential targets for ccRCC immunotherapy. The gene discussed is GZMK; the disease is nonpapillary renal cell carcinoma.